The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review.

OBJECTIVES Patients with RA have an increased prevalence of cardiovascular disease (CVD). This is due to traditional risk factors and the effects of chronic inflammation. MTX is the first-choice DMARD in RA. We performed a systematic literature review to determine whether MTX affects the risk of CVD in patients with RA. METHODS We searched Medline, Embase, Cochrane database, database of abstracts of reviews of effects, health technology assessment and Science Citation Index from 1980 to 2008. Conference proceedings (British Society of Rheumatology, ACR and EULAR) were searched from 2005 to 2008. Papers were included if they assessed the relationship between MTX use and CVD in patients with RA. Two reviewers independently assessed each title and abstract for relevance and quality. RESULTS A total of 2420 abstracts were identified, of which 18 fulfilled the inclusion criteria. Two studies assessed the relationship between MTX use and CVD mortality, one demonstrated a significant reduction in CVD mortality and the second a trend towards reduction. Five studies considered all-cause CVD morbidity. Four demonstrated a significant reduction in CVD morbidity and the fifth a trend towards reduction. MTX use in the year prior to the development of RA decreased the risk of CVD for 3-4 years. Four studies considered myocardial infarction, one demonstrated a decreased risk and three a trend towards decreased risk with MTX use. CONCLUSION The current evidence suggests that MTX use is associated with a reduced risk of CVD events in patients with RA. This suggests that reducing the inflammation in RA using MTX not only improves disease-specific outcomes but may also reduce collateral damage such as atherosclerosis.

[1]  P. V. van Riel,et al.  Disease activity as a risk factor for myocardial infarction in rheumatoid arthritis , 2008, Annals of the rheumatic diseases.

[2]  G. Moneta,et al.  Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein , 2009 .

[3]  H. John,et al.  Hypertension in rheumatoid arthritis. , 2008, Rheumatology.

[4]  D. Symmons,et al.  Rheumatoid factor, smoking, and disease severity: associations with mortality in rheumatoid arthritis. , 2008, The Journal of rheumatology.

[5]  A. Quyyumi,et al.  Rheumatoid arthritis and cardiovascular disease , 2008, Current atherosclerosis reports.

[6]  T. Pincus,et al.  Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study , 2008, Arthritis research & therapy.

[7]  M. Hochberg,et al.  The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006 , 2008, Current medical research and opinion.

[8]  C. Cooper,et al.  Myocardial infarction in rheumatoid arthritis: The effects of DMARDs and prednisolone , 2008 .

[9]  N. Goodson.  The Mortality Association with DMARD Use in Early Inflammatory Polyarthritis , 2008 .

[10]  M. Hochberg,et al.  The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006. , 2008, Current medical research and opinion.

[11]  M. Cutolo,et al.  Impact of long-term anti-TNF-alpha treatment on insulin resistance in patients with rheumatoid arthritis. , 2008, Clinical and experimental rheumatology.

[12]  P. Tak,et al.  Systemic inflammation as a risk factor for atherothrombosis. , 2008, Rheumatology.

[13]  D. Symmons,et al.  Mortality in established rheumatoid arthritis. , 2007, Best practice & research. Clinical rheumatology.

[14]  A. Silman,et al.  Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register , 2007, Arthritis and rheumatism.

[15]  C. Cooper,et al.  The autoantibody rheumatoid factor may be an independent risk factor for ischaemic heart disease in men , 2007, Heart.

[16]  J. Higgins,et al.  Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. , 2007, International journal of epidemiology.

[17]  C. Allaart,et al.  Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. , 2007, Arthritis and rheumatism.

[18]  P. Guerne,et al.  Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis. , 2007, Arthritis and rheumatism.

[19]  E. Kulinskaya,et al.  Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. , 2006, Rheumatology.

[20]  P. McGettigan,et al.  Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. , 2006, JAMA.

[21]  B. Dijkmans,et al.  Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study , 2006, Arthritis research & therapy.

[22]  M. Hudson,et al.  Antirheumatic drug use and the risk of acute myocardial infarction. , 2006, Arthritis and rheumatism.

[23]  A. Drosos,et al.  Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment – a prospective, controlled study , 2006, Arthritis research & therapy.

[24]  C. Cooper,et al.  The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database. , 2005, Rheumatology.

[25]  J. Kleijnen,et al.  Being big or growing fast: systematic review of size and growth in infancy and later obesity , 2005, BMJ : British Medical Journal.

[26]  A. Silman,et al.  Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. , 2005, Arthritis and rheumatism.

[27]  M. Hudson,et al.  Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. , 2005, Rheumatology.

[28]  S. Gabriel,et al.  Cardiovascular death in rheumatoid arthritis: a population-based study. , 2005, Arthritis and rheumatism.

[29]  R. Kirsner,et al.  Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. , 2005, Journal of the American Academy of Dermatology.

[30]  S. Gabriel,et al.  The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. , 2005, Arthritis and rheumatism.

[31]  E. Krishnan,et al.  Declines in Mortality From Acute Myocardial Infarction in Successive Incidence and Birth Cohorts of Patients With Rheumatoid Arthritis , 2004, Circulation.

[32]  Paul M Ridker,et al.  Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? , 2004, Circulation.

[33]  S. Rantapää-Dahlqvist,et al.  Which factors are related to the presence of atherosclerosis in rheumatoid arthritis? , 2004, Scandinavian journal of rheumatology.

[34]  I. McInnes,et al.  Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. , 2003, Circulation.

[35]  M. Braun,et al.  Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist , 2003, Annals of Internal Medicine.

[36]  H. Blom,et al.  Homocysteine Determinants and the Evidence to What Extent Homocysteine Determines the Risk of Coronary Heart Disease , 2002, Pharmacological Reviews.

[37]  B. Joffe,et al.  Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a pilot study , 2002, Arthritis research.

[38]  Hyon K. Choi,et al.  Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. , 2002, The American journal of medicine.

[39]  H. Blom,et al.  Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. , 2002, Rheumatology.

[40]  Tetsuo Shoji,et al.  Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. , 2002, Arthritis and rheumatism.

[41]  M. Tomšič,et al.  Leflunomide and hypertension , 2002, Annals of the rheumatic diseases.

[42]  P. Hannonen,et al.  Long term efficacy and safety of cyclosporin versus parenteral gold in early rheumatoid arthritis: a three year study of radiographic progression, renal function, and arterial hypertension , 2002, Annals of the rheumatic diseases.

[43]  James M Robins,et al.  Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study , 2002, The Lancet.

[44]  B. Dijkmans,et al.  Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity , 2000, The Lancet.

[45]  R. Rau,et al.  Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. , 2000, Arthritis and rheumatism.

[46]  D. Symmons,et al.  Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. , 1998, The Journal of rheumatology.

[47]  D. Symmons,et al.  The clinical management of rheumatoid arthritis and osteoarthritis: strategies for improving clinical effectiveness. , 1998, British journal of rheumatology.

[48]  G. Alarcón,et al.  Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. , 1998, The Journal of rheumatology.

[49]  R. Madhok,et al.  Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis , 1997, Annals of the rheumatic diseases.

[50]  E. McIntosh,et al.  The cost of rheumatoid arthritis. , 1996, British journal of rheumatology.

[51]  K. Aho,et al.  Mortality in rheumatoid arthritis. , 1995, Seminars in arthritis and rheumatism.

[52]  R. Moots,et al.  Corticosteroids: do they damage the cardiovascular system? , 1994, Postgraduate medical journal.

[53]  J. Lifson,et al.  Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study. , 1985, Annals of internal medicine.

[54]  M. Guttadauria,et al.  Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. , 1985, Arthritis and rheumatism.

[55]  M. Weinblatt,et al.  Efficacy of low-dose methotrexate in rheumatoid arthritis. , 1985, The New England journal of medicine.

[56]  J. Esdaile,et al.  A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis. , 1984, The Journal of rheumatology.

[57]  D. Symmons,et al.  Cause of death in rheumatoid arthritis. , 1984, British journal of rheumatology.